What Is IDHIFA (Enasidenib)? Causes, Side Effects, Dosage

 WHAT IS IDHIFA (Enasidenib)?

IDHIFA Medicine
IDHIFA Medicine
IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children.

IDHIFA may cause serious side effects, including:

Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 1 day and up to 5 months after starting IDHIFA. Check the following symptoms below.

  • ·         fever
  • ·         cough
  • ·         shortness of breath
  • ·         swelling of arms and legs
  • ·         fast weight gain (greater than 10 pounds within a week)
  • ·         bone pain

If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine taken by mouth or given through a vein (intravenous) called corticosteroids and may monitor you in the hospital.

How Should I take IDHIFA?

Take IDHIFA Medicine 1 time a day at the same time each day. Swallow IDHIFA tablets whole with 8 ounces (one cup) of water. If you miss a dose of IDHIFA or vomit after taking a dose of IDHIFA, take the dose of IDHIFA as soon as possible on the same day.

Your healthcare provider should do blood tests to check your blood counts before you start IDHIFA treatment and at a minimum of every 2 weeks for at least the first 3 months during treatment to check for side effects

The Most Common Side Effects of IDHIFA include:

  • ·         nausea
  • ·         vomiting
  • ·         diarrhea
  • ·         jaundice
  • ·         decreased appetite

Tell your healthcare provider if you have any changes to the color of your skin or the whites of your eyes.

Location: New Delhi, Delhi, India

Comments

Post a Comment

Popular posts from this blog

The BEST HIV MEDICINE DISTRIBUTOR IN DELHI

Image
  If you're in search of an HIV medication distributor in Delhi, you've come to the right place. There are many options to choose from - NCPI+,Alleviareindia. GSNP+ and a few other brands. Here are some factors to consider. NCPI+ The NCPI+ HIV MEDICINE DISRIBUTOR IN DELHI works to provide HIV medications to people in need in the country. The medicines are incredibly expensive in the open market. However, the government is providing free antiretroviral drugs to 2.1 million people in India. The government procures these drugs through a tender process. The medicines are not readily available at the patient's home, so they need to be transported to the person who needs it most. There are several reasons for this. First, people need to be protected from police. While traveling, they need to present a pass issued by the government or a state AIDS control society. In some cases, police have torn people's green books, forcing them to go without access to the medicines. This has
Read more

What is Byduron? What are their Side Effects?

Image
What is Bydureon (exenatide)? Bydureon is a brand-name medicine used to improve blood sugar levels in people with type 2 diabetes. It comes as a liquid suspension to be given by injection under the skin (subcutaneously). Bydureon contains a medicine called extended-release exenatide. Bydureon vs Bydureon BCise Bydureon BCise is another form of Bydureon. It contains the same medicine (extended-release exenatide). Bydureon and Bydureon BCise work in the same way and have very similar effects in the body. You push the autoinjector against your skin, and it injects the medicine automatically. There are fewer steps required to inject Bydureon using this autoinjector than using a syringe or pen injector. This can make Bydureon BCise easier to use than Bydureon. In clinical studies, Bydureon reduced hemoglobin A1c (HbA1c) by approximately 0.88 to 1.6 percent after 24 to 28 weeks of treatment. In the Bydureon BCise study, HbA1c was reduced by approximately 1.07 to 1.39 percent after
Read more